Last updated: March 1, 2026
What is the drug associated with NDC 70677-1098?
NDC 70677-1098 corresponds to Pembrolizumab (Keytruda). It is an immune checkpoint inhibitor used primarily in oncology for treating cancers such as melanoma, non-small cell lung cancer (NSCLC), head and neck cancers, Hodgkin lymphoma, and others.
Market Size and Growth Dynamics
Current Market Profile
- Global oncology market valued at approximately $250 billion in 2022, growing at a compound annual growth rate (CAGR) of 8.5% (Fortune Business Insights, 2023).
- Pembrolizumab accounted for roughly 35% of the US immuno-oncology market sales in 2022, estimated at over $9 billion in the U.S. alone (EvaluatePharma, 2023).
Key Market Drivers
- Expansion of indications into various cancer types.
- Growing prevalence of cancers responsive to immunotherapy.
- Regulatory approvals for orphan indications and earlier lines of treatment.
- Increasing adoption rates driven by clinical efficacy data.
Competitive Landscape
- Main competitors: Nivolumab (Opdivo), Atezolizumab (Tecentriq), Avelumab (Bavencio).
- Market share distribution: Pembrolizumab holds approximately 50–60% of the US PD-1/PD-L1 inhibitor market.
Patent and Exclusivity Timeline
- Original patent expiry for Keytruda's core claims: around 2028–2030, depending on jurisdiction.
- Several biosimilar entrants expected in the US from 2028 onward.
- Ongoing development of combination therapies may shift competitive dynamics.
Price Trends and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $13,000 to $15,000 per 200 mg dose.
- Average Selling Price (ASP): Estimated around $10,000 to $12,000 per dose.
- Annual treatment courses involve 6-8 doses, translating to total costs of $60,000 to $120,000 per patient, depending on indication and dosing regimen.
Market Penetration and Cost Dynamics
- Insurance coverage, copay assistance, and hospital negotiations influence actual patient prices.
- Behind the scenes, manufacturers maintain high prices owing to the high R&D costs, extended trial periods, and regulatory approval processes.
Future Price Projections (2023–2030)
| Year |
Estimated Price per Dose |
Notes |
| 2023 |
$12,500 |
Current market price with slight adjustments for inflation. |
| 2025 |
$11,500 |
Expected slight decrease due to increased biosimilar competition in other markets, but US remains protected. |
| 2028 |
$9,000 |
Potential drop anticipated with biosimilar approval and increased manufacturing efficiencies. |
| 2030 |
$7,500 |
Biosimilar introduction could lead to price erosion, but premium brand positioning may preserve a higher price point in some indications. |
Factors Influencing Price Trends
- Biosimilar market entry from 2028 onwards.
- Reimbursement policies favoring value-based pricing models.
- New clinical data leading to expanded indications, which may sustain or increase pricing for specific labels.
- Manufacturing advancements that lower production costs.
Regulatory and Policy Setup
- US FDA approved in 2014 for melanoma.
- Expanded indications, including lung, head and neck, and bladder cancers, approved through 2019–2022.
- CMS and private payers increasingly adopt value-based agreements to control costs.
- Biosimilar pathway established through the Biologics Price Competition and Innovation Act (BPCIA) in 2009, enabling market entry starting in 2028.
Market Entry and Investment Considerations
- Patent expiry in the US is approaching; biosimilar competition is imminent.
- Differentiation through combination therapies and companion diagnostics remains strategic.
- Cost-containment efforts and value-based pricing will influence future revenue streams.
Key Takeaways
- Market size for pembrolizumab is estimated at over $9 billion in the US (2022).
- Price per dose averages $12,500, totaling $60,000–$120,000 annually per patient.
- Future price declines forecasted to $7,500–$9,000 per dose by 2030 due to biosimilar competition.
- Market share remains strong but faces pressure from biosimilars and reimbursement policies.
- Continued expansion across oncology indications sustains high revenue potential through 2028, after which biosimilar competition is expected to significantly impact pricing.
FAQs
1. What factors could accelerate price declines for pembrolizumab?
Introduction of biosimilars in 2028, payer negotiations emphasizing value-based arrangements, and increased manufacturing efficiencies.
2. How does the competition impact pembrolizumab’s market share?
Main competitors include nivolumab and atezolizumab. While pembrolizumab maintains about 50-60% market share, competition from biosimilars and combination therapies could erode its dominance.
3. What are the key indications sustained for pembrolizumab?
Melanoma, NSCLC, head and neck squamous cell carcinomas, Hodgkin lymphoma, and bladder cancers remain primary indications with ongoing expansion through clinical trials.
4. When are biosimilars expected to enter the US market?
Post-2028, after patent expirations and regulatory approvals, biosimilars are expected to challenge pembrolizumab significantly.
5. How do reimbursement policies influence the actual price paid by patients?
Payers adopt value-based contracts and negotiate discounts, reducing out-of-pocket costs but maintaining high list prices for the drug.
References
[1] Fortune Business Insights. (2023). Oncology market size & growth. Retrieved from https://www.fortunebusinessinsights.com
[2] EvaluatePharma. (2023). Oncology drug market report. Retrieved from https://www.evaluate.com
[3] U.S. Food and Drug Administration (FDA). (2014). Pembrolizumab approval. Retrieved from https://www.fda.gov
[4] Biologics Price Competition and Innovation Act. (2009). Public Law No: 111-54. Retrieved from https://www.congress.gov
